Proxy Votes Now

Home › Activist investors › Clearline Capital

Clearline Capital

Campaign activist. Positions and campaigns from Clearline Capital’s SEC filings. Updated November 20, 2026.

Filer entities
Clearline Capital LP
SEC CIK
1600136 (Clearline Capital LP)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
Latest 13F
Quarter ended Sep 30, 2026, filed Nov 16, 2026: 115 US-listed positions reported; 12 of 1% or more of a company without a 13D are listed below.
12current positions
7new or changed in 90 days
0active campaigns
1campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (12)

CompanyStakeSourceFirst disclosedLast changeSince previous filingFlagsStated intent
Heron Therapeutics, Inc. 5.81%11,026,633 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 5, 2026 Nov 14, 2018 Decreased Nov 16, 2026 ▼ 0.19 pts Decreased 13F: none stated
Douglas Elliman Inc. 5.16%4,687,915 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 31, 2026 Feb 14, 2024 Increased Nov 16, 2026 ▲ 0.79 pts Increased 13F: none stated
Xperi Inc. 4.90%2,391,827 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 27, 2026 Feb 14, 2023 Decreased Nov 16, 2026 ▼ 0.18 pts Decreased 13F: none stated
Core Scientific, Inc. 2.30%7,422,853 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Nov 2, 2026 Feb 14, 2025 Increased Nov 16, 2026 ▲ 1.07 pts Increased 13F: none stated
Acuren Corporation 1.56%3,411,687 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 May 16, 2025 Decreased Nov 16, 2026 ▼ 0.23 pts Decreased 13F: none stated
MediaAlpha, Inc. 1.55%867,018 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Mar 31, 2026 Aug 15, 2023 Decreased Nov 16, 2026 ▼ 3.31 pts Decreased 13F: none stated
Alkami Technology, Inc. 1.35%1,440,429 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Sep 30, 2026 May 15, 2026 Increased Nov 16, 2026 ▲ 0.92 pts Increased 13F: none stated
Therapeuticsmd, Inc. 5.49%635,222 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 9, 2026 Feb 14, 2017 — 0.00 pts — 13F: none stated
Magnera Corporation 2.07%741,096 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 6, 2026 Feb 14, 2025 — 0.00 pts — 13F: none stated
NCR Voyix Corp. 2.05%2,786,147 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 29, 2026 Feb 17, 2015 — ▲ 0.05 pts — 13F: none stated
Rogers Corporation 1.97%350,202 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 23, 2026 Nov 14, 2024 — ▲ 0.02 pts — 13F: none stated
Blackbaud, Inc. 1.53%688,846 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 26, 2026 Nov 14, 2022 — ▲ 0.01 pts — 13F: none stated

Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.

Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.

Past campaigns (1)
CompanyOutcome or last statusDateFirst filingHighest stageFilingsMeeting / votes
Heron Therapeutics, Inc. Settled (agreement with the company) Jul 24, 2023 Jul 24, 2023 — latest (1) —

How large managers voted in Clearline Capital’s proxy contests (meetings since July 2023)

Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.

No proxy contest has gone to a vote since July 1, 2023.

Track record

How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.

1Settlement
Outcome of each campaign (1)
CompanyOutcomeDetailDateFirst filing
Heron Therapeutics, Inc. Settlement agreement with the company Jul 24, 2023 Jul 24, 2023

Share price after the first 13D

The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 0 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).

Settlement terms

Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.

Heron Therapeutics, Inc. · Jul 24, 2023 · Ownership cap

Other disclosed holders around the same time

Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Clearline Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.

Alkami Technology, Inc. · Clearline Capital first disclosed May 15, 2026 · 2 other filings
HolderFormDateStake
JANA Partners Schedule 13D Apr 1, 2026 5.0%
North Reef Capital Management LP Schedule 13G May 15, 2026 7.2%
Acuren Corporation · Clearline Capital first disclosed May 16, 2025 · 1 other filing
HolderFormDateStake
Sir Martin E. Franklin Schedule 13D Feb 14, 2025 16.4%
Magnera Corporation · Clearline Capital first disclosed Feb 14, 2025 · 2 other filings
HolderFormDateStake
Engine Capital, L.P. Schedule 13D Nov 21, 2024 —
Engine Capital 13F Feb 14, 2025 6.3%
Core Scientific, Inc. · Clearline Capital first disclosed Feb 14, 2025 · 4 other filings
HolderFormDateStake
The Vanguard Group Schedule 13G Jan 30, 2025 6.9%
Tospring Technology Limited Schedule 13G Feb 13, 2025 1.9%
Jericho Capital 13F Feb 14, 2025 7.1%
BlackRock, Inc. Schedule 13G Jul 16, 2025 7.8%
MediaAlpha, Inc. · Clearline Capital first disclosed Aug 15, 2023 · 1 other filing
HolderFormDateStake
White Mountains Insurance Group LTD Schedule 13D Jun 30, 2023 49.9%

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.